Ensysce Biosciences, Inc.
ENSC • NASDAQ
Ensysce Biosciences, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO D. Lynn Kirkpatrick, with a market cap of $1.9M.
CEOD. Lynn Kirkpatrick
Next Earnings
Upcoming earnings announcement for Ensysce Biosciences, Inc.
Date
Tuesday, May 12, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.73
Revenue Estimate
$1.9M
Earnings History
Past 12 earnings reports for Ensysce Biosciences, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 30, 2026 | Q4 2025 | -$0.75Est: -$1.26 | +40.5% | $1.9MEst: $500.0K | +276.4% |  10-K |
| Nov 14, 2025 | Q3 2025 | -$1.29Est: -$0.90 | -43.3% | $493.1KEst: $1.4M | -64.8% | 10-Q |
| Aug 13, 2025 | Q2 2025 | -$0.79Est: -$1.17 | +32.5% | $1.4MEst: $923.8K | +48.4% | 10-Q |
| May 13, 2025 | Q1 2025 | -$1.39Est: -$2.25 | +38.2% | $1.3M | — | 10-Q |
| Mar 10, 2025 | Q4 2024 | -$2.90Est: -$1.95 | -48.7% | $1.3MEst: $245.0K | +432.2% | 10-K |
| Nov 12, 2024 | Q3 2024 | $1.05Est: -$4.35 | +124.1% | $3.4MEst: $250.0K | +1267.6% | 10-Q |
| Aug 14, 2024 | Q2 2024 | -$3.30Est: -$5.85 | +43.6% | $181.8KEst: $300.0K | -39.4% | 10-Q |
| May 13, 2024 | Q1 2024 | -$8.25Est: -$13.95 | +40.9% | $305.7KEst: $400.0K | -23.6% | 10-Q |
| Mar 15, 2024 | Q4 2023 | -$16.95Est: -$13.05 | -29.9% | $515.0KEst: $390.0K | +32.1% | 10-K |
| Nov 9, 2023 | Q3 2023 | -$13.05Est: -$15.90 | +17.9% | $435.4KEst: $590.0K | -26.2% | — |
| Aug 11, 2023 | Q2 2023 | -$14.70Est: -$40.95 | +64.1% | $490.5KEst: $826.7K | -40.7% | 10-Q |
| May 15, 2023 | Q1 2023 | -$31.20Est: -$163.35 | +80.9% | $789.6KEst: $950.0K | -16.9% | — |